Dmitrii A. Sivokhin

Dmitrii A. Sivokhin

Auto-generated profile, based on publicly available information

Dmitrii A. Sivokhin

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2020 in Pathogens
Verified
Journal Article
Open access
PDF file
ASAlexei B. Shevelev
Alexei B. Shevelev
Nicola La PortaNicola La Porta
Nicola La Porta
EIElena Isakova
Elena Isakova
SMStefan Martens
Stefan Martens
YBYulia K Biryukova
Yulia K Biryukova
YDYulia Ivanovna Deryabina
Yulia Ivanovna Deryabina
An increase in the spread of antibiotic-resistant opportunistic microorganisms causes serious problems in the treatment of purulent infections, burns, and trophic ulcers. We tested the antimicrobial activity in vivo of three polyphenols, Resveratrol, Dihydroquercetin (Taxifolin), and Dihydromyricetin (Ampelopsin) from Norway spruce bark to promote the elimination of Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans from wounds. Purulent infection was modelled on wounds in rats infected with suspensions containing 109 CFU (colony-forming unit)/mL of pathogens. The wound area was treated daily with solutions of the polyphenols or placebo for 14 days after the beginning of the treatment. The animals were examined daily, and each stage of the wound healing (inflammation, granulation, and maturation (marginal epithelialisation) was documented. The planimetric analysis of the wound recovery percentage was performed on the 3rd, 10th, and 14th day after the start of curing. Then, one echelon (three or four animals from each subgroup) was withdrawn from the experiment on days 3 (three animals), 10 (three animals), and 14 (four animals) for microscopy analysis of cytological composition of their wound defects by microscopy and microbiological analysis of their contamination with pathogens. Our results show that they are also able to suppress mast cell infiltration and stimulate lymphocyte and macrophage (monocyte) infiltration into the wound. Resveratrol stimulated the replacement of the scar with normal tissue (with a clear boundary between the dermis and epidermis) and the restoration of hair follicles. Resveratrol turned out to be significantly better than some commercial antimicrobial (Levomecol) and antifungal (Clotrimazole) ointments and can be proposed as a promising drug for topical use for the treatment of trophic ulcers and burns.

1 December 2021 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
SSS. V. Starostina
S. V. Starostina
DSD. A. Sivokhin
D. A. Sivokhin
Acute rhinosinusitis is one of the most common diseases in the world. According to statistics, about 10 million cases are registered in Russia every year.Acute bacterial rhinosinusitis (ABRS) in most cases develops as a result of an acute respiratory viral disease, proceeds easily and it does not require antibiotic therapy. However, it significantly reduces the patient's quality of life in cases of moderate and severe disease, and in the absence of timely treatment, can lead to intracranial complications (meningitis, encephalitis, intracranial abscesses, etc.) and orbital (reactive edema of the eyelid, phlegmon of the orbit, periorbital abscesses, etc.). To avoid complications, with exacerbation of rhinosinusitis, it is necessary to choose the right antibiotic therapy, taking into account the resistance of the microorganisms that caused the disease.The article describes the differential diagnosticprinciples of bacterial rhinosinusitis according to the latest recommendations and research in this area, the most common antibiotic-resistant pathogens in the practice of an ENT doctor are presented, the issue of choosing the correct systemic antibiotic therapy for the treatment of patients with moderate and severe acute bacterial rhinosinusitis is considered according to modern data on the sensitivity of bacterial pathogens to antibacterial drugs prescribed in the otorhinolaryngologist's practice. The article presents data on a new universal cephalosporin of the 3rd generation (the active ingredient is cefditoren), as a second- and third-line drug, due to its high activity against most causative agents of acute bacterial rhinosinusitis, and clinical observation using the above antibacterial agent within the framework of the considered topics.

13 May 2022 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
SMS. V. Morozova
S. V. Morozova
ERE. B. Rakunova
E. B. Rakunova
DSD. A. Sivokhin
D. A. Sivokhin
ELE. P. Litvinova
E. P. Litvinova
Acute inflammatory diseases of the upper respiratory tract (URTI) accompanied by cough are one of the most common groups of diseases in the world. It includes acute respiratory viral infections, often manifested by rhinosinusitis, tonsillopharyngitis and laryngitis. According to statistics, about 90% of all infectious diseases are acute respiratory infections, with cough accompanying acute respiratory infections in 83% of cases. Cough largely determines the severity of the disease, and its duration over 4 weeks indicates a high probability of process chronicity. Cough with difficult to detach sputum dramatically reduces the patient’s quality of life, bringing discomfort in everyday activities. In addition to the cough, the problem of viral diseases lies in the rather difficult diagnosis at the outpatient stage, due to which excessive prescription of antibiotics occurs. In order to avoid the occurrence of complications, chronicization of the disease and reduce the level of inappropriate prescriptions of antibacterial drugs, it is necessary to apply therapy, aimed both at the etiology, the links of pathogenesis, and the symptoms in order to alleviate the condition of the patient and his speedy recovery. The processes leading to the development of cough in URTI are described in the article; principles of differential diagnostics and peculiarities of therapy of URTI are reviewed. The article presents data on the use of a natural remedy, ivy leaf extract, which helps to get rid of cough in a shorter period of time, thereby improving the well-being of the patient, and is notable for its good tolerability and rare occurrence of side effects, which may surpass synthetic alternatives.

30 June 2019 in Bulletin of Russian State Medical University
Verified
Journal Article
Open access
YTYa. Ya. Tynio
Ya. Ya. Tynio
GMG. V. Morozova
G. V. Morozova
YBYulia K Biryukova
Yulia K Biryukova
ETElena Vladimirovna Trubnikova
Elena Vladimirovna Trubnikova
MZM. V. Zylkova
M. V. Zylkova
ASAlexei B. Shevelev
Alexei B. Shevelev
Noninvasive stable isotope breath tests allow highly accurate and safe estimation of liver and biliary tract function. The aim of this study was to test 13С-labeled linoleic and linolenic acids intended for diagnostic use for acute and subchronic toxicity. The acids were synthesized using the patented method. A single intragastric administration of the tested compounds to experimental BALB/c mice and Wistar rats in the amounts exceeding clinical doses 500 to 2500-fold did not cause animal death. In the subchronic toxicity test, the rats received 5 to 25 times higher doses than recommended for clinical use in humans. In a 14-day follow-up period, no significant differences were observed between the main and the control groups in terms of weight, blood count (red blood cells, white blood cells, platelets), and blood biochemistry (hemoglobin, total protein, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, bilirubin). The studied compounds are safe at doses intended for oral administration and are recommended for further preclinical and clinical trials.

1 January 2025 in Russian Otorhinolaryngology
Verified
Journal Article
Closed access
DSD. A. Sivokhin
D. A. Sivokhin
MSMikhail Svistushkin
Mikhail Svistushkin
ESE. S. Shchennikova
E. S. Shchennikova
EDE. R. Danelyan
E. R. Danelyan
NKN. P. Knyazheskaya
N. P. Knyazheskaya
MDMoscow Yudin City Clinical Hospital Of Moscow Healthcare Departmen
Moscow Yudin City Clinical Hospital Of Moscow Healthcare Departmen
Introduction. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is predominantly a type 2 inflammation-mediated disease characterized by numerous symptoms that significantly reduce quality of life. In recent years, biological therapy for the treatment of CRSwNP and asthma has dramatically changed the approach to managing these diseases, allowing a significant improvement of the condition of patients. Objective. To determine the dynamics of the most common symptoms affecting patients with CRSwNP and comorbid asthma during biological therapy with dupilumab, depending on the previously used surgical treatment. Patients and Methods. An observational cohort study was conducted involving 45 patients with PRS and bronchial asthma receiving dupilumab therapy. Patients were divided into 3 groups of 15 people: Group 1: patients without a history of surgical interventions associated with the removal of polyps from the nasal cavity and paranasal sinuses, Group 2: patients with a history of a single surgical intervention, Group 3: patients who have undergone 2 or more surgical interventions. Symptoms (nasal congestion, mucous discharge, mucus drip, facial pressure, decreased sense of smell, headache, fatigue, sleep quality) were assessed using VAS before treatment and at 1, 2, 4, 16, and 52 weeks of therapy. Results. In all cases, patients noted a significant improvement in all studied symptoms. However, patients in Group 1 showed the fastest regression of complaints related to nasal congestion, mucous discharge, postnasal drip, sleep disturbances, and frequent awakenings (p ≤ 0.05). The average time for the restoration of the sense of smell after starting biological therapy was 17 days, with only two patients not experiencing the return of smell after one year of treatment. Conclusion. In patients with severe CRSwNP and comorbid asthma, biological therapy with dupilumab reduced the severity of CRSwNP symptoms by more than twofold within one month of treatment. The earliest effect was observed in patients in Group 1.

12 May 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
DSD. A. Sivokhin
D. A. Sivokhin
ESE. S. Shchennikova
E. S. Shchennikova
VRV. V. Royuk
V. V. Royuk
NKN. P. Kniajeskaia
N. P. Kniajeskaia
Chronic Rhinosinusitis with Nasal Polyps (CRwNP) caused by T2 inflammation has a complex pathogenesis, for which treatment options include medical therapy (topical and systemic glucocorticosteroids, leuktriene inhibitors, etc.) and surgical therapy, often recurs and significantly reduces the quality of life for patients. Chronic rhinosinusitis with nasal polyps is common in patients with asthma and, particularly, severe asthma and an allergic reaction to nonsteroidal anti-inflammatory drugs. These conditions are in most cases associated with a common pathogenesis, including a type II immune response, hyperproduction of interleukins (IL) 4, 5 and 13, activation of eosinophils and tissue remodeling. Biological therapy which block the effect of IL-4, 5, 13 can significantly improve the condition of such patients. Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL-4 receptor alpha chain (IL-4Rα), thereby blocking the action of IL-4 and IL-13. Currently, dupilumab is approved for asthma, CRwNP and atopic dermatitis. Dupilumab can reduce the number of exacerbations, treatment with systemic corticosteroids, improve the condition of the upper and lower respiratory tract and achieve an increase in FEV1 by 0.2–0.3 L, which leads to a significant control of these diseases. One of the topical issues is the choice of tactics choice of treatment tactics in patients with CRwNP, asthma and nasal septum deviation. This article presents a clinical case of a patient with severe asthma, CRwNP and deviated nasal septum receiving dupilumab for 4 months.